Spero Therapeutics Targets 2027 Phase II Launch for SP001 in IgG4-Related Disease

Impact · against what's priced in

Spero Therapeutics (SPRO) gains a significant fundamental boost from a $105 million non-dilutive financing deal that extends its runway into H2 2029. While the pivot to IgG4-RD and Sjögren’s disease creates a long-dated catalyst profile (2027), the immediate removal of near-term equity dilution risk is the primary driver.

SPRO+0.60

No priced-in read yet